Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
09/19/2024 | Press release | Distributed by Public on 09/19/2024 15:35
Please select the service you want to use:
Smartlinks | Cielo SA | News | International News | Insurgencies, Conflicts and War | Finance | Security Markets | Security Markets | Company News | Insurgencies, Conflicts and War | Investment Funds | Securities Issuers | Payment and Transaction Service Providers | Frankfurt Stock Exchange | Sao Paulo Stock Exchange (B3) | Berlin Stock Exchange | Stuttgart Stock Exchange | OTC Markets
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact